Brief: Kaleido Biosciences And The COPD Foundation Announce A Strategic Collaboration To Advance KB109 Into Phase 2 Clinical Trial

Kaleido Biosciences

10/08/2021 12:47

Aug 10 (Reuters) - Kaleido Biosciences Inc  KLDO.O :
    * KALEIDO BIOSCIENCES AND THE COPD FOUNDATION ANNOUNCE A
STRATEGIC
COLLABORATION TO ADVANCE KB109 INTO PHASE 2 CLINICAL TRIAL

Source text for Eikon:  ID:nGNX21L7vG 
Further company coverage:  KLDO.O 

 ((Reuters.Briefs@thomsonreuters.com;))